Two US Snuff Factories Achieve Carbon Neutrality

Jun.21.2022
Two US Snuff Factories Achieve Carbon Neutrality
2 US snuff factories have improved their environmental qualifications, achieving carbon neutrality according to PAS 2060.

According to Reynolds American Inc., two snuff factories in the United States have increased their environmental credentials.

 

According to PAS 2060, the Memphis-based snuff company in the United States achieved carbon neutrality in its operations for both Scope 1 and Scope 2 emissions during the period from December 1, 2020 to November 30, 2021.

 

According to PAS 2060, the American snuff company, Taylor Brothers, achieved carbon neutrality in both its Scope 1 and Scope 2 emissions between December 1, 2020 and November 30, 2021.

 

Source: tobaccoreporter

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

UK Vape Distributor JM Wholesale Files Notice to Enter Administration
UK Vape Distributor JM Wholesale Files Notice to Enter Administration
UK vape distributor JM Wholesale filed a notice on March 20 to enter administration. The Leicestershire-based company submitted the notice through Shakespeare Martineau, with Quantuma expected to be appointed as administrator.
Mar.23 by 2FIRSTS.ai
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
British American Tobacco is facing a shareholder lawsuit in London alleging it failed to properly disclose to markets information about breaches of U.S. sanctions linked to its North Korea-related business. BAT agreed in 2023 to pay more than $635 million to U.S. authorities after a subsidiary admitted conspiring to violate U.S. sanctions by selling tobacco products to North Korea and committing bank fraud from 2007 to 2017.
Mar.05 by 2FIRSTS.ai
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Manchester’s Cheetham Hill Hosts 54 Vape Shops Across Two Streets
Cheetham Hill in Greater Manchester has become one of the UK’s most concentrated vape retail clusters, with 54 e-cigarette shops operating along two adjacent streets following a police crackdown on counterfeit goods in the area.
Feb.21
Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarette and e-liquid in new draft law, citing dangerous substances found.
Apr.08 by 2FIRSTS.ai
California federal judge certifies direct purchaser class in Juul–Altria antitrust litigation
California federal judge certifies direct purchaser class in Juul–Altria antitrust litigation
A California federal judge has certified a class of direct purchasers of Juul products in antitrust litigation alleging Juul and Altria conspired to have Altria exit the e-cigarette market.
Mar.02 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11